Afshin Eli Gabayan

1.3k total citations
10 papers, 170 citations indexed

About

Afshin Eli Gabayan is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Afshin Eli Gabayan has authored 10 papers receiving a total of 170 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Hematology. Recurrent topics in Afshin Eli Gabayan's work include Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Afshin Eli Gabayan is often cited by papers focused on Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Afshin Eli Gabayan collaborates with scholars based in United States, Japan and Canada. Afshin Eli Gabayan's co-authors include Peter F. Barnes, D R Radin, Maung Maung Oo, Marti McKinley, Brian G.M. Durie, Elber S. Camacho, John Crowley, Robert Vescio, Jeffrey L. Wolf and Sundar Jagannath and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Afshin Eli Gabayan

9 papers receiving 165 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Afshin Eli Gabayan United States	6	83	82	80	35	27	10	170
Bhuvan Kishore United Kingdom	8	106 1.3×	158 1.9×	83 1.0×	12 0.3×	30 1.1×	39	240
Kenji Nara Japan	5	68 0.8×	121 1.5×	102 1.3×	9 0.3×	18 0.7×	5	170
Alain Mina United States	9	69 0.8×	47 0.6×	70 0.9×	12 0.3×	19 0.7×	31	201
Chantiya Chanswangphuwana Thailand	8	36 0.4×	104 1.3×	69 0.9×	14 0.4×	9 0.3×	36	168
Fauzia Ullah United States	10	66 0.8×	58 0.7×	118 1.5×	34 1.0×	10 0.4×	26	210
Hira Shaikh United States	8	58 0.7×	71 0.9×	101 1.3×	12 0.3×	30 1.1×	48	218
Nathan Visweshwar United States	10	54 0.7×	86 1.0×	95 1.2×	14 0.4×	6 0.2×	31	214
Kota Yoshifuji Japan	6	111 1.3×	57 0.7×	53 0.7×	11 0.3×	45 1.7×	28	208
Rikako Tabata Japan	8	57 0.7×	93 1.1×	83 1.0×	6 0.2×	39 1.4×	35	189
Zoé Van de Wyngaert France	8	81 1.0×	138 1.7×	68 0.8×	7 0.2×	6 0.2×	22	191

Countries citing papers authored by Afshin Eli Gabayan

Since Specialization

Citations

This map shows the geographic impact of Afshin Eli Gabayan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Afshin Eli Gabayan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Afshin Eli Gabayan more than expected).

Fields of papers citing papers by Afshin Eli Gabayan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Afshin Eli Gabayan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Afshin Eli Gabayan. The network helps show where Afshin Eli Gabayan may publish in the future.

Co-authorship network of co-authors of Afshin Eli Gabayan

This figure shows the co-authorship network connecting the top 25 collaborators of Afshin Eli Gabayan. A scholar is included among the top collaborators of Afshin Eli Gabayan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Afshin Eli Gabayan. Afshin Eli Gabayan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Roeland, Eric, Mohamedtaki Abdulaziz Tejani, Eric Cheung, et al.. (2025). A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia.. Journal of Clinical Oncology. 43(16_suppl).

Mohty, Mohamad, Michael H. Tomasson, Bertrand Arnulf, et al.. (2023). Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.. Journal of Clinical Oncology. 41(16_suppl). 8039–8039. 9 indexed citations

Nagasaka, Misako, Shunichi Sugawara, Chang‐Min Choi, et al.. (2022). TRUST-II: A global phase II study for taletrectinib in ROS1 fusion–positive lung cancer and other solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS8601–TPS8601. 4 indexed citations

Lesokhin, Alexander M., Shinsuke Iida, Don A. Stevens, et al.. (2021). Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 138(Supplement 1). 1674–1674. 7 indexed citations

Vaena, Daniel A., Jorge Chaves, Nicholas J. Vogelzang, et al.. (2018). PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS3115–TPS3115. 3 indexed citations

Beatty, Gregory L., Safi Shahda, Thaddeus Beck, et al.. (2018). A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. The Oncologist. 24(1). 14–e10. 36 indexed citations

Beatty, Gregory L., Safi Shahda, J. Thaddeus Beck, et al.. (2017). A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC).. Journal of Clinical Oncology. 35(4_suppl). 362–362. 4 indexed citations

Jagannath, Sundar, Brian G.M. Durie, Jeffrey L. Wolf, et al.. (2009). Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. British Journal of Haematology. 146(6). 619–626. 37 indexed citations

Jagannath, Sundar, Brian G.M. Durie, Jeffrey L. Wolf, et al.. (2006). Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.. Blood. 108(11). 796–796. 32 indexed citations

10.

Oo, Maung Maung, et al.. (1995). Abdominal Tuberculosis in Patients Infected with the Human Immunodeficiency Virus. Clinical Infectious Diseases. 20(4). 938–944. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact